<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

1 min read

A Roller Coaster Quarter: Q220 OrthoBio Market Recap

10/7/20 9:30 AM

Q220 OrthoBio headerCalibrating the craziness and uncertainties of a roller coaster quarter

Because Orthobiologics spans various markets and is used in numerous procedures in different surgical settings, Q2 proved to be a roller coaster of a quarter, creating uncertainty and craziness. Beginning in mid-March with stay-at-home orders and restrictions on elective surgery, US elective procedures bottomed in April, resulting in plummeting revenues and increased angst.

Responding quickly to the new twists and turns of COVID-19, many companies shifted priorities, reduced costs and implemented initiatives to help climb out of the record-breaking descent of Q220. Revenue and procedural recovery varied widely and impacted segments differently.

Among the many topics covered in the comprehensive Q220 OrthoBio  Market Recap* are:

  • Complete OrthoBio Market Overview with Companies' Revenues and Shares
  • The Ups and Downs of the US Bone Replacement Market
  • The Twists and Turns of the US Soft Tissue Market
  • Riding Out 2020
  • Consumer Behavior
  • Surgery/Surgeon Trends
  • The US Economy
  • Notable Developments in Q220
  • Q220 Regulatory Highlights

Like a roller coaster, Q220 was a period of drastic changes that occurred without much warning, causing the blood to pump and the adrenaline to flow. Moving forward SmartTRAK projects that the market will ...

Read the entire Q220 OrthoBio Market Recap including news, data, charts, company revenues and analysis*

*The entire article and the links can only be viewed by SmartTRAK subscribers to this module. For more information on how to receive a demo and subscribe, please click the button below.

Learn More

Kim French
Written by Kim French

20+ years of progressive medical device and biologics marketing and sales experience in orthopedic biological implants, cellular technologies and biopharmaceuticals. Most recent experience includes President, Trilogy Consulting and Marketing and Sales Management roles at AlloSource and Terumo BCT.

  • There are no suggestions because the search field is empty.

Follow Us on Social Media

Recent Articles